1STBIO and D&D Pharmatech's neurodegenerative disease treatment '바카라사이트 쇼미더벳' granted U.S. patent

[by Lee, Young Sung] 1st Biotherapeutics (hereinafter referred to as 1STBIO) and D&D Pharmatech announced on August 5 that they have obtained a U.S. patent for ‘NLY02,’ a co-developed neurodegenerative disease treatment. This patent not only secures the intellectual property rights associated with the compound but is also expected to serve as a key foundation for the companies’ future global technology transfer initiatives.

NLY02 is an orally administered small-molecule compound currently under development for the treatment of neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. The candidate selectively inhibits ‘receptor-interacting serine/threonine-protein kinase 2 (RIPK2),’ a neuroinflammation-inducing signaling protein. NLY02 is presently in the non-clinical phase (IND-enabling study) to assess its therapeutic potential in various animal models.

According to the company, the United States Patent and Trademark Office (USPTO) recognized 바카라사이트 쇼미더벳 as a novel compound with a unique chemical structure distinct from existing technologies. The compound was also acknowledged for presenting innovative and improved methods of application, which contributed to the successful registration of its patent.

The compound has been shown to suppress neuroinflammation and protect dopaminergic neurons in a mouse model of Parkinson's 바카라사이트 쇼미더벳, demonstrating its potential as a fundamental treatment for degenerative brain disorders.

Since entering into a co-development agreement in 2018, 바카라사이트 쇼미더벳 and D&D Pharmatech have maintained close collaborative efforts, capitalizing on their respective areas of expertise. 바카라사이트 쇼미더벳 has been leading compound optimization and preclinical toxicity studies, while D&D Pharmatech has overseen the development of clinical strategies and trial design. In parallel, the two companies are actively engaged in joint discussions with global pharmaceutical companies regarding potential technology transfer opportunities and strategic partnerships.

"The decision to grant a U.S. patent represents a validation of NLY02's innovative mechanism of action and structural uniqueness, marking a significant milestone in the company’s efforts to enter the global market. In collaboration with D&D Pharmatech, we intend to accelerate the development of NYL02 with the goal of obtaining U.S. IND approval and facilitating global technology transfer," stated Jamie Jae Eun Kim, CEO of 1STBIO.

"Through close collaboration, our two companies have successfully identified previously unrecognized pathogenic mechanisms underlying neurodegenerative diseases by targeting novel targets and have discovered new candidate compounds capable of suppressing these targets," expressed Lee Seul-ki, CEO of D&D Pharmatech.

"The U.S. patent registration represents a significant achievement stemming from the collaborative efforts of both companies. Likewise, we will continue to work closely with 1STBIO to pursue meaningful business outcomes," Lee further commented.